Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Pharmaceutical Product (NasdaqNM:PPDI)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials
Location
3151 South Seventeenth Street
Wilmington, NC 28412
Phone: (910) 251-0081
Fax: (910) 343-5920
Email: info@wilm.ppdi.com
Employees (last reported count): 3,700
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Employment
 ·Products & Services
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Index Membership
 ·S&P 600 SmallCap
Ownership
·Insider and 5%+ Owners: 26%
·Over the last 6 months:
 · 11 insider sells; 1.16M shares
  (7.9% of insider shares)
·Institutional: 71% (96% of float)
(345 institutions)
·Net Inst. Buying: 3.18M shares (+7.98%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Pharmaceutical Product Development, Inc. and its subsidiaries provide a broad range of research and development and consulting services in two segments, development and discovery sciences. In the development segment, the Company provides worldwide clinical research and development of pharmaceutical products and medical devices, biostatistical analysis and analytical laboratory services. The discovery sciences services include target identification and validation, compound creation, screening and compound selection. The Company provides services under contract to clients in the pharmaceutical, general chemical, agrochemical, biotechnology and other industries. In addition, the Company performs discovery research on certain compounds for which it holds a license. Development services are marketed primarily in the United States and Europe.
More from Market Guide: Expanded Business Description

Financial Summary
Pharmaceutical Product Development provides a range of research and development and consulting services in the development and discovery science segments. For the six months ended 6/30/01, revenues rose 26% to $209 million. Net income increased 84% to $25 million. Revenues reflect an increase in the size and number of contracts in the global CRO Phase II-IV division. Earnings also reflect increased margins and cost control measures.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Ernest Mario, Ph.D., 62
Chairman
--  --  
Fredric Eshelman, Ph.D., 52
Vice Chairman and CEO
$711K$391K
Philippe Maitre, 44
CFO, VP-Fin., Treasurer
139K--  
Fred Davenport, Jr., 49
Exec. VP
329K90K
Francis Casieri, 58
Sr. VP - Global Bus. Devel.
214K23K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:PPDIAs of 31-Aug-2001
Price and Volume
52-Week Low
on 1-Sep-2000
$11.00 
Recent Price$30.16 
52-Week High
on 11-June-2001
$38.36 
Beta0.08 
Daily Volume (3-month avg)808.2K
Daily Volume (10-day avg)395.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change+145.6%
52-Week Change
relative to S&P500
+229.4%
Share-Related Items
Market Capitalization$1.56B
Shares Outstanding51.9M
Float38.4M
Dividends & Splits
Annual Dividendnone 
Last Split: 2 for 1 on 14-May-2001
Per-Share Data
Book Value (mrq)$5.29 
Earnings (ttm)$0.85 
Earnings (mrq)$0.20 
Sales (ttm)$7.54 
Cash (mrq)$2.29 
Valuation Ratios
Price/Book (mrq)5.70 
Price/Earnings (ttm)35.57 
Price/Sales (ttm)4.00 
Income Statements
Sales (ttm)$388.5M
EBITDA (ttm)$79.8M
Income available to common (ttm)$43.7M
Profitability
Profit Margin (ttm)11.3%
Operating Margin (ttm)15.7%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)12.57%
Return on Equity (ttm)18.31%
Financial Strength
Current Ratio (mrq)2.19 
Debt/Equity (mrq)0.01 
Total Cash (mrq)$119.1M
Short Interest
As of 8-Aug-2001
Shares Short1.20M
Percent of Float3.1%
Shares Short
(Prior Month)
1.76M
Short Ratio1.48 
Daily Volume808.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   B = billions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.